https://www.selleckchem.com/products/brigimadlin.html d of selected species leads to create excessive pressure on them. Unfortunately, the state agencies are not having any robust conservation plan for NTFPs. For long-term management of NTFPs sector, a species-specific conservation strategy, proper harvesting protocol, cultivation practices, the supply of quality planting material, product development and diversification, value chain development, and ensured market is greatly desired. This will not only lead to conserving NTFPs resources in their natural habitats but also lead a sustainable livelihood generation for forest dwellers. Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-acting β -agonist approved for chronic obstructive pulmonary disease. In the development of a once daily, inhaled fixed dose combination (FDC) of indacaterol, glycopyrronium bromide (a long-acting muscarinic antagonist), and mometasone furoate (an inhaled corticosteroid [ICS]) for the treatment of patients with asthma, the acetate salt of indacaterol is used instead of the maleate salt. Here, we investigated the lung function, pharmacokinetics (PK) and safety of indacaterol maleate 150 μg once daily (o.d.) and indacaterol acetate 150 μg o.d. in comparison with placebo. This was a randomised, double-blind, three-period crossover study (ClinicalTrials.gov identifier, NCT03257995) in patients with asthma on background ICS therapy. Patients with percent predicted pre-bronchodilator forced expiratory volume per second (FEV ) ≥50% and ≤ 90% were included in the study. Patients received indacaterol maleate 150 μg o.d., indacaterol a5%; acetate, 0%). In patients with asthma, indacaterol maleate and acetate elicited comparable and significant improvements in lung function compared with placebo and achieved comparable systemic exposure. Both indacaterol salts were safe and well tolerated. ClinicalTrials.gov NCT03257995 June 06, 2017. ClinicalTrials.gov NCT03257995 June